Bristol Myers Squibb May Be 46% Undervalued After Two Fresh FDA Wins

Two recent FDA approvals give Bristol Myers a more concrete case for re-rating

Two FDA wins within roughly two weeks could make BMY look cheap at today's price. That does not prove Bristol Myers is automatically around 46% undervalued. It does suggest the forward earnings-power case just got clearer. If the new indications gain any meaningful traction and the next regulatory decision lands well, the business a few years out could look stronger than the market's current mood implies.

The approvals matter because they give investors something more tangible to evaluate. Earlier this year, the FDA approved Sotyktu for active psoriatic arthritis, broadening the drug's reach. Then last week, the agency approved iberdomide with Darzalex and dexamethasone for relapsed or refractory multiple myeloma, another usable option in a serious cancer setting. Add the Opdivo Hodgkin lymphoma priority review and target action date in April 2026, and the next catalyst is no longer abstract. The clock is visible.

• Bull case: Bristol Myers is showing real regulatory progress again. A company that keeps adding approved use cases becomes harder to dismiss as a one-product story or a pipeline laggard.
• Bear case: An approval is not the same as adoption. Prescribers still have to choose the therapy, patients still have to need it, and payers still have to support access.

That distinction matters. These approvals improve the setup, but they do not remove the need for real-world uptake. Still, that is how a stock story often starts to change: not with a complex model, but with a cleaner path from product attributes to future sales.

What changed with Sotyktu and the iberdomide combo

What improved is not just the headline count. The new approvals create more concrete scenarios for how existing commercial infrastructure could help.

Sotyktu now has a clearer use case in psoriatic arthritis

Sotyktu's PsA approval matters because it is a once-daily oral TYK2 inhibitor and the first TYK2 inhibitor approved for PsA. In practice, that combination can matter: once-daily oral dosing is simpler than more cumbersome regimens, and physicians get another option for patients who need something beyond the usual toolkit. The clinical signal is tangible too, with significantly more patients achieving ACR20 at week 16 than placebo.

The commercial appeal is straightforward: - convenient once-daily dosing - a differentiated mechanism with visible symptom improvement - a broader role for Sotyktu beyond its current footprint

The risk is straightforward as well. A new approval can start the conversation, but adoption still depends on physician habits and payer coverage. Even so, convenience plus clear benefit usually gives a drug a fair chance in immunology.

The iberdomide approval expands later-line myeloma options

The multiple myeloma approval is different in nature, but just as practical. The FDA approved iberdomide with Darzalex and dexamethasone for relapsed or refractory multiple myeloma. Reuters reports that CELMoDs may help the body clear myeloma cells more effectively than older treatments.

That matters because this is a challenging setting. Physicians treating relapsed or refractory myeloma are often looking for regimens that still have biological activity. Adding iberdomide gives them another combination to consider, which broadens Bristol Myers' oncology opportunity alongside Opdivo. The next natural checkpoint for that franchise is the Opdivo Hodgkin lymphoma priority review with a target action date in April 2026. If that review also goes well, investors have a better reason to see a repeatable process rather than a string of isolated wins.

A string of FDA milestones improves the story, not the guarantee

Over the past two years, Bristol Myers has logged a run of FDA milestones across several assets. That does not ensure commercial success, but it does make the company look more operationally credible. Investors can start to believe the organization knows how to move programs through regulatory gateways, not just announce long-dated promises.

The main watchpoints are simple: - Does Sotyktu show up in real prescribing, not just approval headlines? - Does the iberdomide combo become a practical later-line choice? - Does the company carry momentum into the next review cycle?

If those answers stay positive, the market has a cleaner reason to re-rate the business. If they do not, the approvals will still be real milestones, just not the kind that automatically lift the stock.

Why the market may still be too pessimistic-and what would prove it

The approvals improve the story, but the stock only deserves a large re-rating if Bristol Myers can turn them into visible demand.

New approvals only matter if they translate into revenue

The 46% undervaluation claim should be treated as a forward earnings-power argument, not a promise. In plain terms, new approvals only matter if they widen the patient base, support repeat use, or open new lines of therapy that eventually show up in revenue. That is why Bristol Myers may still be mispriced if the market is valuing it like a company that wins approvals but struggles to convert them into durable sales. The thesis is not that everything is fixed. It is that the path just became clearer, and the next decision can show whether that path is real.

The most direct near-term test is close. A positive outcome on the Opdivo Hodgkin lymphoma priority review, with action expected by the April 8, 2026 PDUFA goal date, would do more than add another indication. It would help investors judge whether Bristol Myers has rebuilt a process that can consistently reach the finish line. In market terms, that is the difference between good headlines and believable earnings power.

Where the bull and bear cases actually diverge

Bulls will argue that Bristol Myers no longer asks investors to leap from concept to cash flow without intermediate proof. It already has Sotyktu approved for active psoriatic arthritis, iberdomide with Darzalex and dexamethasone approved for relapsed/refractory multiple myeloma, and a priority review for Opdivo in Hodgkin lymphoma moving through the pipeline. If those therapies get used, future earnings power can widen from a narrower base into something more durable.

Bears have the simpler counter: approvals on paper do not guarantee meaningful uptake. A drug can be clinically useful and still grow slowly, never becoming stock-moving. That is the real boundary here. The thesis works if commercial adoption follows regulatory progress. It weakens if prescriptions move too slowly to matter to earnings on a meaningful timeline.

What investors should watch next

Opdivo catalyst - A positive Opdivo Hodgkin lymphoma decision would be the cleanest proof that the approval streak is real. - If the outcome is practical-more treatment options, credible benefit, no major safety surprise-the stock gets a stronger reason to move beyond approval fatigue.

Sotyktu uptake - Watch for real-world traction in active psoriatic arthritis, especially signs that clinicians are adopting a once-daily oral option. - The key signal is not the press release. It is whether patients and prescribers treat it as a practical next step.

Iberdomide uptake - Watch whether the iberdomide combo becomes a usable part of later-line myeloma care. - In a tougher treatment setting, adoption usually starts with whether oncologists see a meaningful advantage in disease control.

This looks constructive, not certain

The right read is constructive, not euphoric. The opportunity is real if Bristol Myers keeps stringing together approvals and then shows commercial pickup. The cleanest way to test that now is to see whether the Opdivo Hodgkin lymphoma review lands well and whether Sotyktu and iberdomide start showing up in actual prescribing. If that happens, today's price may still be reflecting too much skepticism. If it does not, the approvals will still count as real business progress, just not yet as clear stock upside.